lyophilization cdmo · freeze drying contract manufacturing
Best Lyophilization CDMO Companies in 2026: Top 10 Ranked
August 8, 2026
Updated August 8, 2026
26 min read
A 2026 analyst comparison of the top lyophilization CDMOs, including Catalent, Lonza, Simtra, Vetter, and PCI Pharma Services, covering freeze-dryer capacity, sterile fill-finish specs, recent capacity investments, and how to choose a partner.
10 Leading Lyophilization CDMO Companies in 2026
Executive Summary
This report profiles ten leading lyophilization contract development and manufacturing organizations (CDMOs) for sponsors evaluating freeze-drying partners in 2026: Catalent, Lonza, Thermo Fisher Scientific (through its Patheon CDMO business), Simtra BioPharma Solutions, Recipharm, Vetter Pharma, WuXi STA, Piramal Pharma Solutions, Curia, and PCI Pharma Services. The companies are presented as an editorial shortlist, not in performance order. Lyophilization (freeze-drying) stabilizes injectable drugs by freezing a liquid formulation and removing water under vacuum, and it underlies roughly 30% of parenteral products and 40% of biopharmaceuticals on the market ([1]). Demand for this capacity is expanding quickly: Grand View Research projects the global lyophilization equipment and services market to grow from $5.82 billion in 2026 to $10.63 billion by 2033, at an 8.98% CAGR ([2]), while the sterile injectables CDMO market alone is forecast to rise from $37.82 billion to $87.34 billion over the same period, an 11.2% compound annual growth rate ([3]).
Several of the profiled CDMOs have publicly announced significant sterile-manufacturing or lyophilization capacity commitments since 2021. Simtra BioPharma Solutions is investing over $250 million to expand its Bloomington, Indiana campus, adding a new isolator vial line with three lyophilizers targeted for mid-2027 ([4]). Lonza is building a CHF 500 million, 20,000-square-meter biologics drug product facility in Stein, Switzerland, due in the fourth quarter of 2027 ([5]). PCI Pharma Services describes its lyophilization footprint as one of the industry's largest following its acquisition of Lyophilization Services of New England ([6]) and is installing twin lyophilizers with an integrated filler rated for batches of up to 300,000 vials at its Bedford, New Hampshire campus ([7]). Curia is spending $200 million to expand its Albuquerque, New Mexico site and doubling GMP batch capacity in Glasgow, Scotland to 20,000 vials ([8]).
Selection Methodology
This editorial shortlist profiles ten CDMOs using four publicly disclosed considerations: breadth of lyophilization offering; lifecycle and geographic coverage; specificity of disclosed technical capability; and announced sterile-manufacturing or lyophilization investments. It is not a ranked scorecard, independent quality audit, clinical-quality score, or measure of current manufacturing-slot availability. Public disclosures use non-comparable measures—including network-wide vial output, facility floor area, filling-line counts, batch ceilings, shelf area, and planned equipment—so they do not support a like-for-like ranking. The provider discussions reflect public disclosures available as of August 2026; a disclosed asset may be operating, commissioning, or planned, as indicated in the relevant provider discussion. Sponsors should validate the current operating status, quality-system performance, available manufacturing slots, and technical fit directly with each provider.
The report also profiles five additional niche and regional players—Meribel Pharma Solutions, Halix, Pfizer CentreOne, Fareva, and Lyophilization Technology Inc.—for sponsors with smaller-scale or specialized needs. Selection criteria that matter most, according to industry analysts, include formulation and cycle-development expertise rather than raw freeze-dryer count ([9]), and analysts at L.E.K. Consulting note that fill-finish demand growth is likely to keep outpacing capacity for the next five to ten years despite heavy investment ([10]).
Introduction and Background
Lyophilization, commonly called freeze-drying, stabilizes an injectable drug by freezing a liquid formulation and then removing water under vacuum through sublimation, leaving a porous solid cake that is reconstituted with a diluent before administration. A 2017 conference presentation by Maxwell Korang-Yeboah stated that roughly 30% of parenteral products and approximately 40% of biopharmaceuticals were lyophilized, but the presentation says it reflects the author's views and must not be construed as FDA views or policy ([1]). A contract development and manufacturing organization (CDMO) that offers lyophilization typically combines sterile, aseptic fill-finish (the process of filling vials, syringes, or cartridges under sterile conditions) with cycle development, scale-up, and commercial-scale freeze-drying under one roof.
Demand for this capacity has grown sharply as biologics, biosimilars, GLP-1 (glucagon-like peptide-1) therapies, and cell and gene therapies have expanded the injectable drug pipeline. Analysts at L.E.K. Consulting observe that aseptic fill-finish demand growth continues to outpace available capacity, a dynamic they expect to persist for five to ten years despite significant industry investment ([10]), and trade press coverage describes sponsors facing an 18-month wait to move from initial formulation development to clinical trial supply because of constrained small-batch fill-finish capacity ([11]). The global lyophilization equipment and services market reflects this pressure: Grand View Research projects growth from $5.82 billion in 2026 to $10.63 billion by 2033, at an 8.98% CAGR ([2]).
This report evaluates ten CDMOs with publicly disclosed lyophilization capabilities as of August 2026, based primarily on supplier facility pages and expansion announcements. Those disclosures are useful for initial comparison but are not independent verification of current available capacity. Because life-sciences organizations increasingly manage large, multi-vendor CDMO networks alongside data, quality, and regulatory systems, some sponsors also lean on outside technology and operations advisors. IntuitionLabs, a life-sciences and AI consultancy, describes its work as providing "strategic guidance on digital transformation, AI adoption, and technology roadmapping" for pharmaceutical and life-science organizations ([12]), an adjacent role to the manufacturing CDMOs profiled below rather than a competing option.
Catalent
Capabilities
Catalent operates a global CDMO network of nearly 40 sites worldwide ([13]). Its sterile fill-finish service line combines liquid and lyophilized vial filling with prefilled syringe and cartridge capabilities ([14]), and the company specifically markets lyophilization cycle development for difficult-to-formulate molecules ([15]). Vial filling spans 2R to 20R ISO formats using time-pressure, piston-pump, and peristaltic dispensing technologies ([16]), inside isolator- and restricted-access-barrier-system (RABS)-based aseptic lines that Catalent states meet current EU Annex 1 expectations ([17]).
Adoption
In July 2021, Catalent announced a planned $100 million multi-phase expansion program at its biologics manufacturing facility in Anagni, Italy ([18]) ([19]), part of a broader pattern of sterile fill-finish and lyophilization capacity investment across the CDMO sector.
Strengths and Limitations
Catalent's near 40-site global footprint gives sponsors broad geographic optionality for technology transfer and multi-region supply ([13]). The company's public technical pages describe filling formats and dispensing technologies in detail but do not disclose specific freeze-dryer unit counts or shelf-area figures, a level of granularity that some smaller specialist CDMOs publish more openly.
Lonza
Capabilities
Lonza offers lyophilization cycle development, scale-up, and robustness testing as part of its drug product process development services ([20]). The company's Stein, Switzerland site is being expanded into a 20,000-square-meter biologics drug product facility, scheduled to open in the fourth quarter of 2027 ([21]), supported by a CHF 500 million investment intended to deliver scalable, technology-enabled manufacturing ([5]).
Adoption
In September 2021, Lonza announced a new aseptic filling line in Stein supporting liquid and lyophilized vial filling, cartridges, and prefilled syringes ([22]), which at the time brought Lonza's global drug product manufacturing and fill-finish capacity to three sites. In October 2025, Lonza announced the operational readiness of its new aseptic drug product filling line in Stein following Swissmedic approval ([23]).
Strengths and Limitations
Lonza's Stein expansion represents one of the largest single lyophilization-capable investments among the ten CDMOs profiled, but its Q4 2027 target date means sponsors evaluating near-term commercial capacity will need to weigh the facility's construction timeline against existing operational lines elsewhere in Lonza's network.
Thermo Fisher Scientific (Patheon)
Capabilities
Thermo Fisher Scientific, operating its CDMO services under the Patheon brand, produces more than 130 million sterile liquid and lyophilized vials annually across its network ([24]). Its Greenville, North Carolina site performs sterile dose manufacturing, filling, and lyophilization for both biopharmaceuticals and small molecules ([25]), backed by $150 million in total investment in sterile capabilities since 2015 ([26]). The company's Swindon, UK facility specializes in integrated sterile liquid and lyophilized product development and commercial manufacturing ([27]).
Adoption
With the addition of a Ridgefield, New Jersey site, Thermo Fisher's sterile fill-finish footprint now spans seven sites worldwide, including three in the United States ([28]). Thermo Fisher Scientific, the parent company, reported full-year 2025 revenue of $44.56 billion, up 4% year over year ([29]), giving the CDMO division access to the balance sheet of one of the largest life-sciences companies globally.
Strengths and Limitations
Thermo Fisher's 130-million-vial annual output figure suggests some of the highest aggregate throughput among the profiled CDMOs, though this figure spans the company's full sterile network rather than lyophilization capacity alone, so sponsors should confirm site-specific freeze-dryer availability during technical diligence.
Simtra BioPharma Solutions
Capabilities
Simtra BioPharma Solutions maintains a Lyophilization Center of Excellence co-located with its two manufacturing facilities in Bloomington, Indiana, and Halle/Westfalen, Germany ([30]), and the company offers robotic loading and unloading of lyophilizers to minimize manual handling and microbial exposure risk ([31]). Simtra describes itself as a CDMO with over 65 years of sterile injectable manufacturing experience ([32]).
Adoption
Simtra's Bloomington, Indiana campus, at 600,000 square feet, is described as one of the largest contract manufacturers of sterile products in North America ([33]). Simtra states it is implementing a $250+ million facility expansion in Bloomington to add vial and syringe fill lines and increase lyophilization capacity ([34]), including a new 300,000-square-foot building targeted for mid-2027 that will house a GMP-ready, high-speed isolator vial line with three lyophilizers for high-potency drugs, including antibody-drug conjugates ([4]). Its Halle/Westfalen, Germany site is undergoing a separate $100 million expansion adding syringe manufacturing capacity ([35]).
Strengths and Limitations
Simtra's dual-continent Center of Excellence and named commitment to three specific lyophilizers in its upcoming Bloomington building give sponsors an unusually concrete equipment picture ahead of the facility's opening; the tradeoff is that this new high-potency capacity will not be operational until mid-2027, so near-term projects depend on existing lines.
Recipharm
Capabilities
Recipharm offers extensive in-house capability to develop and optimize lyophilization cycles in its research and development laboratories, with scale-up support through commercial production ([36]). Its service offering includes disposable, single-use system manufacturing options across an extensive range of ISO-standard vial sizes ([37]).
Adoption
Recipharm's Masate, Italy site has more than four decades of experience in parenteral manufacturing and lyophilization ([38]), and its Wasserburg, Germany site is described as a leading European center of excellence for sterile manufacturing, aseptic filling, and lyophilization ([39]). Recipharm previously invested $43 million to build a fourth production area with large-scale freeze-drying capability at Wasserburg ([40]). The company operates 16 facilities across 8 countries globally ([41]).
Strengths and Limitations
Recipharm's decades-long lyophilization heritage at Masate and Wasserburg is well documented, though the company's public pages describe vial sizes only in general "ISO standard" terms rather than the specific millimeter or milliliter ranges that some competitors publish, which sponsors will need to confirm directly during technical evaluation.
Vetter Pharma
Capabilities
Vetter Pharma provides lyophilization support across the injectable product lifecycle, from lab-scale freeze-drying for initial studies through commercial-scale lyophilization for global market supply ([42]). All three of Vetter's commercial manufacturing sites offer commercial-scale lyophilization services for injectable therapies ([43]), and the company developed a proprietary cleanroom technology, V-CRT, that combines isolator-like quality standards with the flexibility of restricted-access barrier systems ([44]).
Adoption
Vetter's Ravensburg South facility hosts six of the company's 21 active filling lines, which process both liquid and lyophilized products in vials, syringes, and cartridges ([45]). That 21-line figure is company-wide; Vetter separately states that its three commercial fill-finish sites in southern Germany have 17 filling lines ([46]). The company reports that 80% of active commercial customer projects involve complex biologics ([47]). Vetter states 76 years of experience as an independent family business, reporting €1.26 billion in preliminary 2025 revenue from its specialized aseptic filling services and more than 7,400 employees worldwide ([48]).
Strengths and Limitations
Vetter's independent, family-owned structure and concentrated southern Germany footprint give it a focused biologics specialization, reflected in its 80% complex-biologics project mix, though sponsors requiring manufacturing outside Europe or North America (Vetter also operates a Chicago clinical facility) will find a narrower geographic network than some global CDMOs offer ([42]).
WuXi STA
Capabilities
WuXi STA, the small-molecule and drug-product CDMO arm of WuXi AppTec, operates a Wuxi City, China site featuring 12 plants, including high-potency drug products in both oral and injectable formulations ([49]). Its injectable manufacturing lines support solutions, emulsions, suspensions, and lyophilized powders across different filling formats, including vials, prefilled syringes, and cartridges ([50]).
Adoption
In January 2022, WuXi STA launched its first fully automatic parenteral formulation manufacturing line, which operates in a full isolation system with a built-in lyophilizer and an annual capacity of 2 million units ([51]). In July 2023, the company debuted a high-potency sterile injectable line equipped with two 20-square-meter lyophilizers, supporting liquid and lyophilized vials with a filling rate of up to 200 units per minute ([52]). WuXi AppTec, the parent company, reported 2025 total revenue of RMB 45.46 billion, with revenue from continuing operations up 21.4% year over year ([53]).
Strengths and Limitations
WuXi STA discloses two 20-square-meter lyophilizers and a 200-units-per-minute fill rate for its high-potency line, providing useful equipment detail for high-volume programs. Those lyophilizers are not among the largest individual units disclosed in this comparison: PCI reports individual Bedford units of 430 square feet (about 40 square meters). Sponsors outside Asia should weigh the added logistics of a China-centered manufacturing base against planned additions in Switzerland and Delaware.
Piramal Pharma Solutions
Capabilities
Piramal Pharma Solutions offers sterile compounding, fill-finish, and lyophilization capabilities from preclinical through commercial stages at its Lexington, Kentucky site ([54]). The site's lyophilization equipment includes two pilot-scale 6.4-square-foot SP Scientific LyoStar lyophilizers and one manufacturing-scale 48-square-foot Hull lyophilizer ([55]), with isolator-based vial capabilities ranging from 2 mL to 100 mL for liquid products and 2 mL to 50 mL for lyophilized products ([56]).
Adoption
Piramal's Lexington site history includes a 2017 $25 million capacity expansion and a 2024 $84 million expansion designed to increase production capacity, enhance commercial-scale capabilities, and improve operational efficiency ([57]). Separately, in September 2024, Piramal announced an $80 million investment plan adding two commercial-size lyophilizers and other equipment, intended to raise the Lexington site's annual batch capacity from 104 batches per year at current peak utilization to over 240 annual batches by the first quarter of 2027 ([58]) ([59]). Piramal Pharma Solutions operates a global CDMO network spanning three continents and 15 facilities ([60]).
Strengths and Limitations
Piramal's disclosure of specific lyophilizer models and shelf areas at Lexington gives sponsors an unusually granular equipment picture for technical diligence, and the planned batch-capacity more than doubling by 2027 signals substantial forward capacity; the near-term ceiling of 104 batches per year at current peak utilization means sponsors with large near-term programs should confirm slot availability before the expansion completes.
Curia
Capabilities
Curia (formerly AMRI) is a CDMO with over 30 years of experience, an integrated network of more than 20 global sites, and 3,100 employees ([61]). Its Albuquerque, New Mexico commercial site offers bulk capacity of 1 to 1,200 liters with GMP dose filling lines validated for 2 to 100 mL vials and 1 to 10 mL syringes, supporting both liquid and lyophilized formats for standard and highly potent products ([62]).
Adoption
In March 2025, Curia announced it will add an integrated, isolator-based vial filling line and lyophilizer at its Glasgow, UK site, more than doubling current GMP batch size ([63]), increasing batch sizes up to 20,000 vials with robotic, lossless filling technology inside an isolator. Curia is separately investing $200 million in a multi-year expansion at Albuquerque, adding a new high-speed vial line with two autoloaded freeze dryers supporting 2R to 30R vials ([64]).
Strengths and Limitations
Curia has announced transatlantic lyophilization-capacity expansions at Glasgow and Albuquerque. Its March 2025 announcement described the Glasgow line as planned, the Albuquerque VarioSys line as undergoing commissioning, and the high-speed Albuquerque line as scheduled to begin commissioning in Q3 2025; sponsors should confirm current operating status and slot availability directly with Curia ([65]). Its 3,100-employee, 20-plus-site network is smaller in absolute scale than global majors like Thermo Fisher or Catalent.
PCI Pharma Services
Capabilities
PCI Pharma Services has more than 25 years of experience in large-scale bulk lyophilization, managing freeze-drying, harvesting, and packaging of medical devices, drug intermediates, and APIs (active pharmaceutical ingredients) ([66]). Its bulk freeze-drying capacity scales up to lyophilizers accommodating 195 disposable Lyoguard trays, or 260 square feet. Through its acquisition of Lyophilization Services of New England (LSNE), PCI states it offers one of the industry's largest and fully scalable lyophilization capacities ([6]), and has developed over 675 lyophilization cycles for clients ([67]).
Adoption
PCI began installing twin lyophilizers and a large-scale isolator filling line at its Bedford, New Hampshire campus in 2024, as part of a multi-year $100 million capital investment project ([68]). The new facility features twin 430-square-foot lyophilizers with automatic loading and unloading systems; the integrated filler is rated for batch sizes up to 300,000 vials at up to 400 vials per minute ([7]). As of its current site network, PCI Pharma Services reports over 8,000 people across 38 global GMP facilities ([69]).
Strengths and Limitations
PCI's LSNE-derived lyophilization fleet and its 675-plus developed cycles suggest deep process-development experience, and the Bedford campus's 300,000-vial batch and 430-square-foot lyophilizer specifications are among the largest disclosed in this comparison. PCI said in June 2025 that the facility was approaching full-scale GMP production that summer, and its May 2026 update describes the large-scale isolator fill-finish and lyophilization line as added; sponsors should still confirm current slot timing directly ([70]) ([71]).
Feature Comparison
Table 1 below summarizes publicly reported lyophilization capability, format range, and recent investment for the ten primary CDMOs profiled in this report, drawn primarily from supplier facility and capability pages as of August 2026. “Planned” entries are not current operating capacity, and supplier-reported metrics use non-comparable units.
| Company | Reported Lyophilization Sites / Network Footprint | Notable Lyophilizer / Capacity Detail | Vial / Batch Format Range | Recent Sterile-Manufacturing Capacity Investment |
|---|---|---|---|---|
| Catalent | Network of nearly 40 sites worldwide; Anagni, Italy is included in the network ([13]) | Isolator/RABS aseptic lines meeting EU Annex 1 | 2R to 20R ISO vials ([16]) | $100M, Anagni, Italy (2021) ([18]) |
| Lonza | Stein, Switzerland (3 global drug product/fill-finish sites) ([22]) | New 20,000 sqm biologics DP facility, opening Q4 2027 ([21]) | Liquid and lyophilized vials, cartridges, prefilled syringes | CHF 500M, Stein (through 2027) ([5]) |
| Thermo Fisher (Patheon) | 7 sterile sites worldwide incl. Greenville NC, Swindon UK ([28]) | 130M+ sterile liquid/lyo vials/year network-wide ([24]) | Commercial and clinical vial formats | $150M, sterile capabilities since 2015 ([26]) |
| Simtra BioPharma Solutions | Bloomington, IN and Halle/Westfalen, Germany ([30]) | New isolator vial line with 3 lyophilizers, mid-2027 target ([4]) | 13mm to 20mm vial opening diameters | $250M+ Bloomington; $100M Halle/Westfalen ([72]) |
| Recipharm | Masate, Italy; Wasserburg, Germany (16 sites, 8 countries) ([41]) | Single-use lyophilization system options ([37]) | ISO-standard vial range | $43M, Wasserburg (large-scale freeze-drying) ([40]) |
| Vetter Pharma | 3 commercial sites, southern Germany; Chicago (clinical) ([46]) | 21 active filling lines company-wide; 17 at the three southern Germany commercial sites; V-CRT cleanroom technology ([45]) | Batches under 10,000 to 500,000 units | Ongoing organic capacity growth; €1.26B preliminary 2025 revenue ([48]) |
| WuXi STA | Wuxi City, China (12 plants); Couvet CH and Middletown DE planned | Two 20 sqm lyophilizers, 200 units/min fill rate ([52]) | Vials, prefilled syringes, cartridges ([50]) | 12M units/year line capacity (2023 line) ([73]) |
| Piramal Pharma Solutions | Lexington, KY (3 continents, 15 facilities total) ([60]) | 2 pilot 6.4 sqft LyoStar + 1 mfg-scale 48 sqft Hull lyophilizer | 2 to 100 mL liquid; 2 to 50 mL lyophilized vials | $80M, Lexington (targeting 240+ batches/yr by Q1 2027) ([59]) |
| Curia | Albuquerque, NM; Glasgow, UK (20+ global sites) | Announced: 2 autoloaded freeze dryers at Albuquerque; planned Glasgow batches up to 20,000 vials | 2 to 100 mL vials; 2R to 30R vial range ([62]) | $200M Albuquerque multi-year expansion; March 2025 update said one line was commissioning and the high-speed line was scheduled for Q3 2025 commissioning ([65]) |
| PCI Pharma Services | Bedford, NH (LSNE); 38 global GMP facilities ([69]) | One of the industry's largest lyophilization capacities; twin 430 sqft units (Bedford) ([6]) | Batches up to 300,000 vials, 400/min (Bedford) | $100M, Bedford, NH (multi-year) |
The comparison shows that scale definitions vary widely across the industry: WuXi STA discloses lyophilizer shelf area, Lonza discloses the floor area of a planned drug-product facility, Curia and PCI disclose vial-batch ceilings, and Vetter discloses filling-line counts. These measures are not directly comparable. Sponsors should normalize the relevant figures to their own program's batch size and vial format before treating any single metric as decisive.
Performance and Benchmarks
Translating disclosed capacity figures into comparable performance benchmarks requires care, because CDMOs report different units. On raw batch-size ceilings, PCI Pharma Services' Bedford, New Hampshire line, rated for up to 300,000 vials per batch at up to 400 vials per minute, and Curia's Glasgow expansion, rated for batches up to 20,000 vials, sit at different points on the clinical-to-commercial spectrum: Bedford's figures describe a large commercial filler feeding into twin 430-square-foot lyophilizers ([7]), while Glasgow's 20,000-vial ceiling reflects a mid-scale clinical-to-early-commercial line.
On shelf-area terms, a commercial-scale industry-standard freeze dryer can span 2 to 45 square meters of shelf area with condenser capacity up to 800 kilograms ([74]), a range that WuXi STA's disclosed two 20-square-meter units fall within ([52]). Piramal discloses a manufacturing-scale 48-square-foot (roughly 4.5-square-meter) Hull lyophilizer at Lexington; shelf area alone does not establish the appropriate program stage or batch fit. On fill-rate terms, WuXi STA's disclosed 200-units-per-minute rate on its 2023 high-potency line is roughly half of PCI's disclosed 400-units-per-minute Bedford rate, though fill rate alone does not capture downstream lyophilization cycle time, which for many biologics runs 24 to 96 hours regardless of upstream fill speed.
Several profiled CDMOs have announced substantial sterile-manufacturing and lyophilization expansions since 2021, including Lonza's CHF 500 million Stein project ([5]) and Simtra's over $250 million Bloomington expansion ([34]). Trade press coverage attributes this wave of investment to biologics, biosimilars, and GLP-1 therapies driving sustained demand for sterile drug product capacity ([75]), with analysts describing near-term CDMO market growth for injectables in the high single digits ([76]).
How to Choose a Lyophilization CDMO Partner
Evaluating a lyophilization CDMO requires weighing several factors beyond headline capacity numbers. Industry guidance emphasizes that what matters more than freeze-dryer capacity is whether the CDMO's team can understand the formulation, interpret stability and cycle data correctly, and use that insight to guide development ([9]). A practical evaluation checklist typically includes:
- Formulation assessment and development: capability to screen excipients and stabilizers before cycle design begins ([77]).
- Analytical testing to characterize product behavior throughout freeze-drying, including moisture content, reconstitution time, and cake appearance.
- Data-driven cycle development, rather than trial-and-error approaches, to shorten development timelines.
- Scale-up and technology transfer support, ensuring a cycle proven at pilot scale reproduces reliably at commercial scale.
- Aseptic classification and equipment protection: the FDA recommends that the area immediately adjacent to the aseptic processing line meet, at a minimum, Class 10,000 (ISO 7) conditions ([78]), and that the transfer area between the filling line and the lyophilizer itself provide Class 100 (ISO 5) protection, because containers enter the chamber only partially stoppered ([79]).
- Throughput and format compatibility, including vial, syringe, and cartridge formats and any specialized handling needs such as cold-chain logistics ([80]).
Cost is another differentiator sponsors should model early. PCI Pharma Services estimates that lyophilized drug products can cost 50% to 70% more to manufacture than comparable liquid fill-finish products ([81]); the differential will vary by molecule, batch size, cycle duration, and facility utilization. Longer cycle times, specialized equipment, and additional analytical release testing can contribute to higher cost.
Table 2 below lists five additional CDMOs with smaller-scale or regionally specialized lyophilization offerings that may suit sponsors whose programs do not require the largest global networks.
| Company | Region / Specialization | Notable Capability | Best Fit For |
|---|---|---|---|
| Meribel Pharma Solutions | Europe (11 sites) | 15 freeze-dryers, including 3 dedicated to sterile freeze-dried products ([82]) | Sponsors needing bulk API or non-sterile lyophilization alongside sterile options |
| Halix | Netherlands (Leiden) | Processes over a million vials per year ([83]), 5.0 sqm commercial lyophilizer | Biologics sponsors wanting integrated bioreactor-to-fill-finish services |
| Pfizer CentreOne | US and Europe (multiple sites) | Over four decades of aseptic lyophilization and liquid fill-finish experience ([84]) | Sponsors seeking a large pharma-affiliated CDMO with multi-region capacity |
| Fareva | France (Pau/Idron) | New GMP sterile pilot unit with 2 sqm lyophilizer; batches of 200 to 8,000 vials ([85]) | Early-phase sponsors needing flexible small-batch runs |
| Lyophilization Technology, Inc. (LTI) | US (specialist) | Over 500 biotech/pharma clients served across 900+ products in 25+ years ([86]) | Early formulation and cycle-development work ahead of a larger-scale CDMO handoff |
Sponsors weighing the tradeoff between a large global network and a specialist boutique should also consider technology and program-management overhead. Because life-sciences organizations often coordinate several CDMO relationships alongside internal quality, regulatory, and data systems, some sponsors supplement in-house teams with outside advisors. IntuitionLabs, describing its own positioning, states it is "empowering pharmaceutical and life science organizations with cutting-edge AI solutions" ([87]) for functions such as commercial analytics and enterprise system integration; such firms operate alongside, rather than in place of, the manufacturing CDMOs compared in this report.
Data Analysis and Evidence
Table 3 summarizes the market-size and growth data underlying the demand pressures discussed throughout this report, drawn from named market research originators.
| Market Segment | Base Year Value | Projected Value | CAGR | Horizon |
|---|---|---|---|---|
| Lyophilization equipment and services | $5.82B (2026) | $10.63B | 8.98% | 2026–2033 ([2]) |
| Sterile injectables CDMO market | $37.82B (2025) | $87.34B | 11.2% | 2033 ([3]) |
| Fill-finish pharmaceutical contract manufacturing | $17.95B (2024) | $29.06B | 8.3% | 2030 ([88]) |
| Freeze drying equipment (broader industrial + pharma) | $2,138.9M (2025) | $4,261.6M | 9.1% | 2033 ([89]) |
A second market research publisher places the lyophilization equipment market at $7.32 billion in 2025, growing to $8.13 billion in 2026 ([90]). This estimate and the $5.36 billion equipment-and-services estimate above are from different publishers with non-comparable methodologies and scope definitions; notably, the equipment-market estimate includes related services sold by equipment creators. Sponsors should therefore treat either market-size figure as directional rather than precise. Within the sterile injectables CDMO market specifically, North America held the largest regional share, accounting for 33.7% in 2025 ([91]), and as of March 2024 more than 581 clinical trials in North America were focused on cell therapies, a pipeline factor cited as driving sterile injectables CDMO demand ([92]).
Regulatory scrutiny of lyophilized products remains significant: the FDA's inspection technical guide on lyophilization of parenterals notes that inspections have historically disclosed potency and sterility problems associated with the manufacture and control of lyophilized products ([93]). That finding reinforces the importance of careful cleanroom and transfer-area design, while the FDA guidance described in the previous section remains nonbinding unless a specific legal requirement applies. A peer-reviewed regulatory analysis similarly identified manufacturing-related deficiencies across a total of 263 new drug applications and abbreviated new drug applications submitted for lyophilized injectable products ([94]). On the approvals side, LyoHub's "Lyophilization in Review" analysis found that in 2019 the FDA approved a total of 47 lyophilized drug applications submitted by 37 companies ([95]), of which 87% were generic products and 9% were new drug applications ([96]), while the European Medicines Agency (EMA) approved 4 lyophilized drugs that year, split across oncology, infectious disease, and metabolic disease indications ([97]).
On equipment scale, a 2023 peer-reviewed freeze-drying process design study illustrates how commercial dryers compare to pilot units, noting that a larger production dryer with 42 square meters of shelf area behaves differently from smaller development-scale equipment during scale-up ([98]), and the same study notes that vials are typically equilibrated for at least 30 minutes after loading before the cooling phase of a cycle begins ([99]). A commercial freeze dryer specification sheet from an equipment manufacturer describes a mid-size unit with a 9.72 square meter shelf area across nine shelves ([100]), providing a useful reference point against which to compare the CDMO-disclosed capacities in Table 1.
Implications and Future Directions
Two technology trends are likely to reshape lyophilization CDMO selection over the next several years. First, continuous and semi-continuous freeze-drying approaches, such as spin freeze-drying and suspended-vial trains, have the potential to reduce vial-to-vial heterogeneity in heat and mass transfer compared with conventional shelf freeze-drying ([101]), though the pace of commercial adoption varies and should be verified directly with prospective providers. Second, process analytical technology (PAT), tools that allow real-time monitoring and control of a freeze-drying cycle within a validated design space ([102]), remains underused in commercial manufacturing: a peer-reviewed analysis found that only 4.17% of new drug applications and 0.85% of abbreviated new drug applications incorporated PAT tools in their manufacturing processes ([103]). Regulatory pressure toward Quality by Design, in which manufacturers specify critical process parameters and control them within predefined design-space limits, has been building since the FDA's Pharmaceutical CGMPs for the 21st Century initiative began in 2003 ([104]), which should gradually push PAT adoption higher among CDMOs seeking to differentiate on process robustness.
Emerging cycle technologies also point toward faster development timelines: microwave-assisted freeze-drying has been shown in early research to shorten drying time significantly while maintaining product efficacy and stability for a monoclonal antibody formulation ([105]), though such techniques remain in the research and early-adoption phase rather than widespread commercial use. Regulatory scrutiny is likely to keep intensifying in parallel: a peer-reviewed review of FDA inspection reports from 2015 through 2019 found that 52% of the 201 reports examined cited an average of 1.8 objectionable conditions directly tied to the lyophilization unit operation industry-wide ([106]), underscoring why the transfer-area and cleanroom classification standards discussed earlier remain relevant to CDMO technical audits.
On the demand side, biologics, biosimilars, GLP-1 therapies, and advanced therapies are expected to keep driving sterile fill-finish and lyophilization investment ([75]), with the CDMO market for injectables expected to grow at a high single-digit pace in the near term ([76]). Analysts attribute part of the persistent capacity lag to the machine manufacturing process itself: aseptic filling and lyophilization equipment is largely hand-tooled, which makes it difficult to scale production of the equipment quickly even when CDMOs commit capital ([107]). Sponsors should therefore expect lead times for new capacity, whether reserving slots on existing lines or securing priority access to a CDMO's next expansion, to remain a defining feature of lyophilization sourcing through the rest of this decade.
Conclusion
The ten profiled CDMOs—Catalent, Lonza, Thermo Fisher Scientific (Patheon), Simtra BioPharma Solutions, Recipharm, Vetter Pharma, WuXi STA, Piramal Pharma Solutions, Curia, and PCI Pharma Services—have publicly documented lyophilization capabilities as of August 2026. Each brings a distinct combination of geographic footprint, equipment scale, and specialization: Simtra, Lonza, and Curia are adding named capacity on defined timelines; PCI discloses twin 430-square-foot lyophilizers and a 300,000-vial batch capability, while WuXi STA discloses two 20-square-meter lyophilizers and a 200-units-per-minute fill rate; and Vetter and Piramal offer deep, well-documented process expertise at a somewhat smaller absolute scale.
No single metric determines the right fit. A sponsor evaluating a large-molecule biologic destined for global commercial launch will weigh network breadth and cleanroom classification differently than an early-stage company seeking flexible, small-batch clinical trial material. The five additional niche and regional players profiled, Meribel Pharma Solutions, Halix, Pfizer CentreOne, Fareva, and Lyophilization Technology Inc., offer viable paths for sponsors whose programs do not require the largest global networks. Across the companies discussed, publicly announced capacity projects are an important consideration, although disclosure timing, scope, and investment amounts vary by company. Analysts expect demand growth to keep outpacing capacity for years to come. Sponsors who begin technical and capacity diligence early, and who evaluate formulation and cycle-development expertise alongside raw equipment counts, are best positioned to secure reliable freeze-drying partnerships in an increasingly constrained market.
Sources / 107
Need Expert Guidance on This Topic?
Let's discuss how IntuitionLabs can help you navigate the challenges covered in this article.
I'm Adrien Laurent, Founder & CEO of IntuitionLabs. With 25+ years of experience in enterprise software development, I specialize in creating custom AI solutions for the pharmaceutical and life science industries.
The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein. Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document. This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it. All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders. IntuitionLabs.ai is an AI software development company specializing in helping life-science companies implement and leverage artificial intelligence solutions. Founded in 2023 by Adrien Laurent and based in San Jose, California. This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.
Related Articles
Viral Vector CDMO Comparison: AAV Capacity & Lead Times
A 2026 analyst comparison of viral vector and gene therapy CDMOs covering AAV manufacturing capacity, bioreactor scale up to 5,000L, regulatory track records, and 8 to 18 month lead times across Catalent, Lonza, and 10 other providers.
Top 10 Best Sterile Fill-Finish CDMOs in 2026 (Ranked)
A 2026 analyst ranking of the top 10 sterile fill-finish CDMOs, covering isolator vs RABS technology, prefilled syringe capacity, EU Annex 1 compliance, and capital investment data for Lonza, Thermo Fisher, Catalent, and more.
Top CDMO Companies 2026: Largest Contract Manufacturers Ranked
A 2026 analyst ranking of the top CDMO companies by revenue and capacity, covering Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fisher, plus CDMO vs CMO vs CRO differences and $150B+ market data.